Literature DB >> 31040191

One-Time Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD (DETECT Study).

Germaine Wong1,2,3, Richard L Hope4, Kirsten Howard5, Jeremy R Chapman2, Antoni Castells6,7,8, Simon D Roger9, Michael J Bourke4, Petra Macaskill5, Robin Turner5,10, Gabrielle Williams5,3, Wai Hon Lim11, Charmaine E Lok11, Fritz Diekmann12, Nicholas B Cross13,14, Shaundeep Sen15, Richard D M Allen16, Steven J Chadban16,17, Carol A Pollock18, Allison Tong5,3, Armando Teixeira-Pinto5,3, Jean Y H Yang19, Narelle Williams5,3, Eric Hoi Kit Au5,3, Anh Kieu5,3, Laura James5,3, Jonathan C Craig20.   

Abstract

BACKGROUND: In patients with CKD, the risk of developing colorectal cancer is high and outcomes are poor. Screening using fecal immunochemical testing (FIT) is effective in reducing mortality from colorectal cancer, but performance characteristics of FIT in CKD are unknown.
METHODS: To determine the detection rates and performance characteristics of FIT for advanced colorectal neoplasia (ACN) in patients with CKD, we used FIT to prospectively screen patients aged 35-74 years with CKD (stages 3-5 CKD, dialysis, and renal transplant) from 11 sites in Australia, New Zealand, Canada, and Spain. All participants received clinical follow-up at 2 years. We used a two-step reference standard approach to estimate disease status.
RESULTS: Overall, 369 out of 1706 patients who completed FIT (21.6%) tested positive; 323 (87.5%) underwent colonoscopies. A total of 1553 (91.0%) completed follow-up; 82 (4.8%) had died and 71 (4.2%) were lost. The detection rate of ACN using FIT was 6.0% (5.6%, 7.4%, and 5.6% for stages 3-5 CKD, dialysis, and transplant). Sensitivity, specificity, and positive and negative predictive values of FIT for ACN were 0.90, 0.83, 0.30, and 0.99, respectively. Of participants who underwent colonoscopy, five (1.5%) experienced major colonoscopy-related complications, including bowel perforation and major bleeding.
CONCLUSIONS: FIT appears to be an accurate screening test for patients with CKD, such that a negative test may rule out the diagnosis of colorectal cancer within 2 years. However, the risk of major complications from work-up colonoscopy are at least ten-fold higher than in the general population.
Copyright © 2019 by the American Society of Nephrology.

Entities:  

Keywords:  cancer; chronic kidney disease; screening; test performance

Mesh:

Year:  2019        PMID: 31040191      PMCID: PMC6551781          DOI: 10.1681/ASN.2018121232

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  32 in total

Review 1.  Informed choice for screening: implications for evaluation.

Authors:  Les Irwig; Kirsten McCaffery; Glenn Salkeld; Patrick Bossuyt
Journal:  BMJ       Date:  2006-05-13

Review 2.  Cancer screening in renal transplant recipients: what is the evidence?

Authors:  Germaine Wong; Jeremy R Chapman; Jonathan C Craig
Journal:  Clin J Am Soc Nephrol       Date:  2008-03       Impact factor: 8.237

3.  Cancer incidence before and after kidney transplantation.

Authors:  Claire M Vajdic; Stephen P McDonald; Margaret R E McCredie; Marina T van Leeuwen; John H Stewart; Matthew Law; Jeremy R Chapman; Angela C Webster; John M Kaldor; Andrew E Grulich
Journal:  JAMA       Date:  2006-12-20       Impact factor: 56.272

4.  Fecal occult blood tests. A cost-effectiveness analysis.

Authors:  D Gyrd-Hansen
Journal:  Int J Technol Assess Health Care       Date:  1998       Impact factor: 2.188

5.  [Principles and practice of mass screening for disease].

Authors:  J M Wilson; Y G Jungner
Journal:  Bol Oficina Sanit Panam       Date:  1968-10

6.  Cost-effectiveness of colorectal cancer screening in renal transplant recipients.

Authors:  Germaine Wong; Kirsten Howard; Jonathan C Craig; Jeremy R Chapman
Journal:  Transplantation       Date:  2008-02-27       Impact factor: 4.939

7.  The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy.

Authors:  M Akmal; S Sawelson; F Karubian; M Gadallah
Journal:  Clin Nephrol       Date:  1994-09       Impact factor: 0.975

8.  Health benefits and costs of screening for colorectal cancer in people on dialysis or who have received a kidney transplant.

Authors:  Germaine Wong; Margaret W Y Li; Kirsten Howard; Danny K Hua; Jeremy R Chapman; Michael Bourke; Robin Turner; Allison Tong; Jonathan C Craig
Journal:  Nephrol Dial Transplant       Date:  2012-11-25       Impact factor: 5.992

9.  Colorectal Cancer Screening Programme in Spain: Results of Key Performance Indicators After Five Rounds (2000-2012).

Authors:  Gemma Binefa; Montse Garcia; Núria Milà; Esteve Fernández; Francisco Rodríguez-Moranta; Núria Gonzalo; Llúcia Benito; Ana Clopés; Jordi Guardiola; Víctor Moreno
Journal:  Sci Rep       Date:  2016-01-20       Impact factor: 4.379

10.  Epidemiology of cancer in end-stage renal disease dialysis patients: a national cohort study in Taiwan.

Authors:  Chih-Chiang Chien; Ming-Ming Han; Yu-Hsien Chiu; Jhi-Joung Wang; Chin-Chen Chu; Chien-Ya Hung; Yih-Min Sun; Nai-Cheng Yeh; Chung-Han Ho; Chih-Ching Lin; Hao-Yun Kao; Shih-Feng Weng
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

View more
  5 in total

1.  Fecal Immunochemical Screening for Advanced Colorectal Neoplasia in Patients with CKD: Accurate or Not?

Authors:  Michael G Collins; Erin L Symonds; Peter A Bampton; P Toby Coates
Journal:  J Am Soc Nephrol       Date:  2019-10-09       Impact factor: 10.121

Review 2.  De Novo Malignancies after Kidney Transplantation.

Authors:  David Al-Adra; Talal Al-Qaoud; Kevin Fowler; Germaine Wong
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-29       Impact factor: 8.237

Review 3.  Emerging Concepts in Managing Malignancy in Kidney Transplant Patients.

Authors:  Brittany Schreiber; Maen Abdelrahim; Ala Abudayyeh; Naoka Murakami
Journal:  Semin Nephrol       Date:  2022-01       Impact factor: 4.472

4.  Health-Related Quality of Life in People Across the Spectrum of CKD.

Authors:  Anoushka Krishnan; Armando Teixeira-Pinto; Wai H Lim; Kirsten Howard; Jeremy R Chapman; Antoni Castells; Simon D Roger; Michael J Bourke; Petra Macaskill; Gabrielle Williams; Charmaine E Lok; Fritz Diekmann; Nicholas Cross; Shaundeep Sen; Richard D M Allen; Steven J Chadban; Carol A Pollock; Robin Turner; Allison Tong; Jean Y H Yang; Narelle Williams; Eric Au; Anh Kieu; Laura James; Anna Francis; Germaine Wong; Jonathan C Craig
Journal:  Kidney Int Rep       Date:  2020-10-03

Review 5.  Assessment of kidney transplant suitability for patients with prior cancers: is it time for a rethink?

Authors:  Wai H Lim; Eric Au; Anoushka Krishnan; Germaine Wong
Journal:  Transpl Int       Date:  2019-08-28       Impact factor: 3.782

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.